Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME)

Clinical Infectious Diseases

Volumn 63, Issue 6, 2016, Pages 812-817

  Evans, Scott R ^a,b   Pennello, Gene ^c   Pantoja Galicia, Norberto ^c   Jiang, Hongyu ^b   Hujer, Andrea M ^d   Hujer, Kristine M ^d   Manca, Claudia ^e   Hill, Carol ^f   Jacobs, Michael R ^d   Chen, Liang ^e   Patel, Robin ^g   Kreiswirth, Barry N ^e   Bonomo, Robert A ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^f DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^g MAYO CLINIC   (United States)

Author keywords

benefit risk; diagnostic yield; diagnostics; pragmatism

Indexed keywords

IMIPENEM; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL DECISION MAKING; CONCEPTUAL FRAMEWORK; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; EVALUATION STUDY; PRIORITY JOURNAL; SPECIES; ACTINOBACTERIA; ANTIBIOTIC RESISTANCE; CLINICAL DECISION SUPPORT SYSTEM; COMPUTER ASSISTED DIAGNOSIS; GRAM POSITIVE INFECTION; HUMAN; PREVALENCE; PROCEDURES; RISK ASSESSMENT; STATISTICAL MODEL;

ACTINOBACTERIA; ANTI-BACTERIAL AGENTS; DECISION SUPPORT SYSTEMS, CLINICAL; DIAGNOSIS, COMPUTER-ASSISTED; DRUG RESISTANCE, BACTERIAL; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MODELS, STATISTICAL; PREVALENCE; RISK ASSESSMENT;

EID: 84995395633     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw329     Document Type: Article

References (16)

1. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life oriented endpoint for comparing treatments. Biometrics 1989; 45:781-95.
2. Chuang-Stein C, Mohberg NR, Sinkula MS. Three measures for simultaneously evaluating benefits and risks using categorical data from clinical trials. Stat Med 1991; 10:1349-59.
3. Follmann D. Regression analysis based on pairwise ordering of patients' clinical histories. Stat Med 2002; 21:3353-67.
4. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33:176-82.
5. Egan JP. Signal detection theory and ROC analysis. New York: Academic Press, 1975.
6. Evans SR, Rubin D, Follmann D, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis 2015; 61:800-6.
7. Evans SR, Hujer AM, Jiang H, et al. Rapid molecular diagnostics, antibiotic treatment decisions, developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016; 62:181-9.
8. Evans SR, Jiang H, Hujer AM, et al. Informing antibiotic treatment decisions: evaluating rapid molecular diagnostics (RMDs) to identify susceptibility and resistance to carbapenems against Acinetobacter spp. PRIMERS-III. In: ID Week 2015, San Diego, CA. Poster 1604, Abstract 52116, Session 227.
9. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002; 58:657-64.
10. Gail MH, Pfeiffer RM. On criteria for evaluating models of absolute risk. Biostatistics 2005; 6:227-39.
11. Green DM, Swets JA. Signal detection theory and psychophysics. New York: Wiley, 1966.
12. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26:565-74.
13. Baker SG. Putting risk into perspective: relative utility curves. J Natl Cancer Inst 2009; 101:1538-42.
14. Clark RB, Lewinski MA, Loeffelholz MJ, Tibbetts RJ. Cumitech 31A: verification and validation of procedures in the clinical microbiology laboratory. Sharp SE, ed. Washington, DC: ASM Press, 2009.
15. US Department of Health and Human Services, Food and Drug Administration, Centers for Devices and Radiological Health. Guidance on review criteria for assessment of antimicrobial susceptibility devices, 1991. Available at: http://www. fda. gov/ohrms/dockets/98fr/000109gd. pdf. Accessed 9 April 2016.
16. US Department of Health and Human Services, Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www. cdc. gov/drugresistance/pdf/ar-threats-2013-508. pdf. Accessed 11 February 2016.